Compare Abeona Therapeutics Inc (ABEO) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs AngloGold Ashanti Limited — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while AngloGold Ashanti Limited trades at $99.1 (market cap $49.19B). The key difference: AngloGold Ashanti Limited is far larger — about 115.9× Abeona Therapeutics Inc's market cap, and AngloGold Ashanti Limited pays a 4.65% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AU | |
|---|---|---|
Market Cap | $424.33M | $49.19B |
Sector | Health | Basic Materials |
52-Week High | $7.45 | $128.26 |
52-Week Low | $4.17 | $52.15 |
Enterprise Value | $279.23M | $48.20B |
Dividend Yield | — | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
AngloGold Ashanti (AU) surged 9.85% to $96.22 on strong gold price momentum and positive Q2 earnings. The stock trades near its 52-week high with bullish technical indicators and robust fundamentals including 26.64% net margins and 46.5% ROE. Recent quarterly results showed mixed performance with Q1 beating expectations while Q2 slightly missed, but strong free cash flow growth supports increased shareholder returns including dividends and a $2 billion buyback program.
Outlook remains positive with analyst consensus at $120.33 target (25% upside) and 64% buy ratings. Key catalysts include H2 production growth and gold price strength, while risks involve operational disruptions and commodity volatility. The company's improving balance sheet and cash generation support continued dividend payments and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
